GC-FID optimization and validation for determination of 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxyamphetamine and methamphetamine in ecstasy tablets
- 178 Downloads
A methodology for the determination of 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxyamphetamine (MDA) and methamphetamine (MA) in seized tablets using gas chromatography with a flame ionization detector (GC-FID) is described. The chromatographic conditions, i.e. gas flow rates and temperatures for the column, injector and detector were optimized. The optimum chromatographic conditions were as follows: a CP-SIL 24 CB WCOT fused silica capillary column (30 m × 0.32 mm I.D., 0.25 μm film thickness), N2 carrier gas flowing at 2.6 mL/min, injector temperature at 290°C and detector temperature at 300°C. The oven temperature was ramped from 80°C at a rate of 20°C/min to final temperature of 270°C (1 min). All analytes were well separated within 7 min with an analysis time of 10.5 min. Calibration curves were linear over the concentration ranges of 3.125–200 μg/mL for MDMA and 6.25–200 μg/mL for MDA and MA (r > 0.990). The intra- and inter-day precisions for determining all analytes were 2.32–10.38% RSD and 1.15–9.77% RSD, respectively. The intra- and inter-day accuracies ranged from −19.79 to +17.51% DEV and −6.84 to +5.2% DEV, respectively. The lower limits of quantification (LLOQs) were 3.125 μg/mL for MDMA and 6.25 μg/mL for MDA and MA. All analytes were stable at room temperature during 24 h but significant loss occurred after 2-month storage at −20°C. The method was shown to be useful for determining the purity of MDMA in seized tablets.
Unable to display preview. Download preview PDF.
- 1.Gahlinger, P.M., Am. Fam. Physician, 2004, vol. 69, no. 11, p. 2619.Google Scholar
- 2.National Institute on Drug Abuse. MDMA (Ecstasy). 2006; http://www.nida.nih.gov/infofacts/ecstasy.html
- 3.Kalant, H., Can. Med. Assoc. J., 2001, vol. 165, no. 7, p. 917.Google Scholar
- 5.Office of the Narcotics Control Board. Narcotics Act of B.E. 2522 (1979); http://www1.oncb.go.th/document/Narcotics%20Act%20B.E.2522%20p10-40.pdf
- 13.De Martinis, B.S., Barnes, A.J., Scheidweiler, K.B., and Huestis, M.A., J Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2007, vol. 852, no. 1–2, p. 450.Google Scholar
- 21.Maresová, V., Chadt, J., and Prikryl, L., Neuro Endocrinol. Lett., 2006, vol., 27, suppl. 2, p. 121.Google Scholar
- 25.United States Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. 2001; http://www.fda.gov/cder/guidance/4252fnl.pdf
- 27.Kosin, P. and Klew-aom, T., Physical and chemical characterization of ecstasy tablets; http://www.dmsc.moph.go.th/webroot/drug/rd/eDrug.stm